Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 12/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.49 |
| ▸ | ATR | Q13535 | 10/20 | 0.49 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15805519 | 1.00 | PDCD1 (0.49) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL2369761 | 1.00 | PDCD1 (0.49) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL15805551 | 0.87 | MTOR (0.52) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL20692991 | 0.87 | MTOR (0.52) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL2513264 | 0.87 | ATR (0.48) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL15805552 | 0.87 | MTOR (0.52) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL15805547 | 0.87 | MTOR (0.52) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL20797863 | 0.87 | ATR (0.48) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL15805506 | 0.87 | MTOR (0.52) | PDCD1CD274CHEK1ATRATRIP | |
| SCHEMBL9978858 | 0.86 | ATR (0.46) | PDCD1CD274CHEK1ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| EP-3668839-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| WO-2020244613-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | 北京泰德制药股份有限公司 | 2020-12-10 | — | — | WO | disclosed |
| CN-111886224-A | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2020-11-03 | — | — | CN | disclosed |
| CN-111867590-A | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2020-10-30 | — | — | CN | disclosed |
| US-10800774-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2019036641-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| WO-2019014618-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014618-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-17 | — | — | WO | disclosed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014090147-A1 | PYRIMIDINE DERIVATIVES AND SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2014-06-19 | — | — | WO | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800774-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | PDCD1 1244/4885CD274 3110/4885CHEK1 2/4885 |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | PDCD1 1284/4885CD274 3430/4885CHEK1 2/4885 |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | PDCD1 2737/4885CD274 4168/4885CHEK1 1638/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PDCD1 1284/4885CD274 3430/4885CHEK1 2/4885 |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PDCD1 1284/4885CD274 3430/4885CHEK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.